CD40 and B-cell chronic lymphocytic leukemia: However, a direct modulation of miR-181b in CLL cells, concomitant with T cell activation or CD40-CLL stimulation, could be therapeutically effective for the above-described refractory patients and a valid alternative for the management of all CLL patients.